Javascript must be enabled to continue!
The Neuronal Ischemic Tolerance Is Conditioned by the Tp53 Arg72Pro Polymorphism
View through CrossRef
Abstract
Cerebral preconditioning (PC) confers endogenous brain protection after stroke. Ischemic stroke patients with a prior transient ischemic attack (TIA) may potentially be in a preconditioned state. Although PC has been associated with the activation of pro-survival signals, the mechanism by which preconditioning confers neuroprotection is not yet fully clarified. Recently, we have described that PC-mediated neuroprotection against ischemic insult is promoted by p53 destabilization, which is mediated by its main regulator MDM2. Moreover, we have previously described that the human
Tp53 Arg72Pro
single nucleotide polymorphism (SNP) controls susceptibility to ischemia-induced neuronal apoptosis and governs the functional outcome of patients after stroke. Here, we studied the contribution of the human
Tp53 Arg72Pro
SNP on PC-induced neuroprotection after ischemia. Our results showed that cortical neurons expressing the Pro72-p53 variant exhibited higher PC-mediated neuroprotection as compared with Arg72-p53 neurons. PC prevented ischemia-induced nuclear and cytosolic p53 stabilization in Pro72-p53 neurons. However, PC failed to prevent mitochondrial p53 stabilization, which occurs in Arg72-p53 neurons after ischemia. Furthermore, PC promoted neuroprotection against ischemia by controlling the p53/active caspase-3 pathway in Pro72-p53, but not in Arg72-p53 neurons. Finally, we found that good prognosis associated to TIA within 1 month prior to ischemic stroke was restricted to patients harboring the Pro72 allele. Our findings demonstrate that the
Tp53 Arg72Pro
SNP controls PC-promoted neuroprotection against a subsequent ischemic insult by modulating mitochondrial p53 stabilization and then modulates TIA-induced ischemic tolerance.
Title: The Neuronal Ischemic Tolerance Is Conditioned by the Tp53 Arg72Pro Polymorphism
Description:
Abstract
Cerebral preconditioning (PC) confers endogenous brain protection after stroke.
Ischemic stroke patients with a prior transient ischemic attack (TIA) may potentially be in a preconditioned state.
Although PC has been associated with the activation of pro-survival signals, the mechanism by which preconditioning confers neuroprotection is not yet fully clarified.
Recently, we have described that PC-mediated neuroprotection against ischemic insult is promoted by p53 destabilization, which is mediated by its main regulator MDM2.
Moreover, we have previously described that the human
Tp53 Arg72Pro
single nucleotide polymorphism (SNP) controls susceptibility to ischemia-induced neuronal apoptosis and governs the functional outcome of patients after stroke.
Here, we studied the contribution of the human
Tp53 Arg72Pro
SNP on PC-induced neuroprotection after ischemia.
Our results showed that cortical neurons expressing the Pro72-p53 variant exhibited higher PC-mediated neuroprotection as compared with Arg72-p53 neurons.
PC prevented ischemia-induced nuclear and cytosolic p53 stabilization in Pro72-p53 neurons.
However, PC failed to prevent mitochondrial p53 stabilization, which occurs in Arg72-p53 neurons after ischemia.
Furthermore, PC promoted neuroprotection against ischemia by controlling the p53/active caspase-3 pathway in Pro72-p53, but not in Arg72-p53 neurons.
Finally, we found that good prognosis associated to TIA within 1 month prior to ischemic stroke was restricted to patients harboring the Pro72 allele.
Our findings demonstrate that the
Tp53 Arg72Pro
SNP controls PC-promoted neuroprotection against a subsequent ischemic insult by modulating mitochondrial p53 stabilization and then modulates TIA-induced ischemic tolerance.
Related Results
Response To Azacitidine Is Independent Of TP53 Mutations In Higher-Risk Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (sAML)
Response To Azacitidine Is Independent Of TP53 Mutations In Higher-Risk Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (sAML)
Abstract
Introduction
Higher-risk myelodysplastic syndromes (MDS) progress to secondary acute myeloid leukemia (sAML) within mon...
Effect of TP53 Arg72Pro and MDM2 SNP309 Polymorphisms on the Risk of High-Grade Osteosarcoma Development and Survival
Effect of TP53 Arg72Pro and MDM2 SNP309 Polymorphisms on the Risk of High-Grade Osteosarcoma Development and Survival
Abstract
Purpose: The germ-line polymorphisms TP53 Arg72Pro and MDM2 SNP309 T>G are risk factors for tumor development and affect response to chemotherapy and...
Comparison of TP53 Alterations in Hematological Malignancies
Comparison of TP53 Alterations in Hematological Malignancies
Abstract
Background: TP53 is altered in ~50% of human cancers. Alterations include mutations and deletions. Both frequently occur together, supportin...
High Resolution Melt Analysis for Rapid and Cost-Effective Screening of TP53 Mutations in Patients with Myeloid Malignancies
High Resolution Melt Analysis for Rapid and Cost-Effective Screening of TP53 Mutations in Patients with Myeloid Malignancies
Abstract
Background
Recent reports have highlighted an adverse impact of TP53 mutations on the prognosis of patients with myeloid malignancies. TP53 m...
Abstract 4442: TP53 hot spot mutations in ovarian cancer: Selective resistance to microtubule stabilizing agents in monoclonal cells and comparison of clinical outcomes from The Cancer Genome Atlas data
Abstract 4442: TP53 hot spot mutations in ovarian cancer: Selective resistance to microtubule stabilizing agents in monoclonal cells and comparison of clinical outcomes from The Cancer Genome Atlas data
Abstract
TP53 is mutated in 96% of high grade serous epithelial ovarian carcinomas (HGS EOC) sequenced by The Cancer Genome Atlas (TCGA). Missense mutations at hot s...
Abstract 5865: Novel allosteric STING agonists in combination with DNA methyltransferase inhibitors induce an interferon-driven apoptotic response in TP53-mutated acute myeloid leukemia
Abstract 5865: Novel allosteric STING agonists in combination with DNA methyltransferase inhibitors induce an interferon-driven apoptotic response in TP53-mutated acute myeloid leukemia
Abstract
TP53-mutated acute myeloid leukemia (AML) has dismal outcomes; new therapies are needed, and immunotherapeutic approaches are being explored. STimulator of ...
Coopération des mutations CALR et TP53 dans la transformation leucémique des néoplasmes myéloprolifératifs
Coopération des mutations CALR et TP53 dans la transformation leucémique des néoplasmes myéloprolifératifs
Cooperation of CALR and TP53 mutations in the leukemic transformation of myeloproliferative neoplasms
Les néoplasmes myéloprolifératifs (NMP) sont des maladies clon...
Metabolically induced neuronal differentiation
Metabolically induced neuronal differentiation
In recent years, several neuronal differentiation protocols were published that circumvent the requirement of embryoid body (EB) formation under serum-deprivation and simplified me...

